
Align Technology, Inc.
NASDAQ•ALGN
CEO: Mr. Joseph M. Hogan
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2001-01-30
Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth. The segment also provides Invisalign moderate, lite and express packages, and Invisalign go and Invisalign Go Plus; retention products, Invisalign training, and adjusting tools used by dental professionals during the course of treatment; and Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and orthodontists software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers. This segment also provides Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface designed to enhance dental consultations; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan, as well as subscription software, disposables, rentals, leases, pay per scan, and CAD/CAM software solutions. The company was incorporated in 1997 and is headquartered in Tempe, Arizona.
Contact Information
Market Cap
$11.36B
P/E (TTM)
30.3
32.2
Dividend Yield
--
52W High
$237.23
52W Low
$122.00
52W Range
Rank26Top 9.6%
5.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$995.69M+1.82%
4-Quarter Trend
EPS
$0.78-49.68%
4-Quarter Trend
FCF
$122.19M-47.75%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Total Revenue Slightly Decreases Nine months net revenues totaled $2.99B USD, down 0.5% from prior period, driven by lower Clear Aligner ASPs.
Net Income Declines Nine months net income fell to $274.6M USD, a decrease of $43.0M USD compared to the prior year period.
Strong Cash Balances Maintained Cash and cash equivalents stood at $1.006B USD as of September 30, 2025, providing ample liquidity for operations.
Aligner Volume Growth Continues Clear Aligner case volume increased 3.7% for nine months to 1.93M units, despite revenue decline due to ASP pressure.
Risk Factors
2025 Restructuring Expenses Initiated 2025 restructuring plan anticipates $40.0M to $50.0M in total expenses, impacting near-term operating results.
Macroeconomic Uncertainty Impacts Demand Global macroeconomic conditions, tariffs, and geopolitical tensions continue to impede dental patient demand and future sales.
Inventory Impairment Recorded Recognized $14.9M inventory impairment loss in Q3 2025, recorded to Cost of net revenues, impacting gross margin.
Ongoing Antitrust Litigation Exposure Unable to predict outcomes for antitrust lawsuits; potential loss estimates cannot be determined at this time.
Outlook
Stock Repurchase Program Status April 2025 Repurchase Program has $928.4M remaining authorization; $523.2M spent in the first nine months of 2025.
Workforce Realignment Completion 2025 workforce realignment plan is ongoing, anticipated to incur $40.0M to $50.0M, concluding in the fourth quarter 2025.
FY2025 Capital Expenditures Forecast Anticipated capital expenditures for fiscal year 2025 are approximately $100M USD, focused on manufacturing and technology upgrades.
Focus on Product Innovation Strategy centers on international expansion, GP treatment adoption, and continuous innovation to meet evolving customer demands.
Peer Comparison
Revenue (TTM)
DVA$13.32B
HSIC$12.94B
$4.83B
Gross Margin (Latest Quarter)
PEN67.8%
ALGN64.2%
62.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| PEN | $12.41B | 75.5 | 13.1% | 12.4% |
| GMED | $11.83B | 28.1 | 10.0% | 2.3% |
| ALGN | $11.36B | 30.3 | 9.8% | 1.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.0%
Moderate Growth
4Q Net Income CAGR
-18.2%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Feb 4, 2026
EPS:$2.99
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 5, 2025|Revenue: $995.69M+1.8%|EPS: $0.78-49.7%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 6, 2025|Revenue: $1.01B-1.6%|EPS: $1.72+34.4%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 8, 2025|Revenue: $979.26M-1.8%|EPS: $1.27-9.3%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 28, 2025|Revenue: $4.00B+3.5%|EPS: $5.63-3.3%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 5, 2024|Revenue: $977.87M+1.8%|EPS: $1.55-2.5%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 2, 2024|Revenue: $1.03B+2.6%|EPS: $1.28-12.3%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 3, 2024|Revenue: $997.43M+5.8%|EPS: $1.40+22.8%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 28, 2024|Revenue: $3.86B+3.4%|EPS: $5.82+26.0%Beat